Is Iradimed Co (IRMD) overvalued? · P/E 51, rev $73.2M
Iradimed Co (IRMD) is a medical devices company listed on US.
This page asks whether Iradimed Co (IRMD) looks expensive on cached numbers — not a short thesis.
Latest reported IRMD revenue for 2024-12-31 was $73.2M. Net income was $19.2M. Revenue was up 11.7% from 2023-12-31 to 2024-12-31. IRMD currently screens at market cap $1.19B and trailing P/E 50.9.
IRMD currently screens at market cap $1.19B and trailing P/E 50.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IRMD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IRMD stock page for the full model, not this heading.
Not investment advice.